

Samalizumab

Cat. No.:	HY-P99400
CAS No.:	1073059-33-2
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Samalizumab (ALXN 6000) is a humanized monoclonal antibody that specifically binds to CD200 and blocks its ligation to the CD200 receptor (CD200R). Samalizumab can be used for multiple myeloma and B-cell chronic lymphocytic leukemia research ^[1] .
In Vitro	Samalizumab is rationally engineered with an Ig G2/G4 constant region to minimize effector function and preserve immune cell subsets. Samalizumab is a first-in-class, recombinant humanized anti-CD200 mAb, engineered to ablate effector function, that specifically binds to the immune checkpoint CD200, blocks receptor engagement and signaling and antagonizes CD200-driven immune suppression, thereby mount an anti-tumor immune response ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Daruka Mahadevan, et al. Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200. J Immunother Cancer. 2019 Aug 23;7(1):227.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA